The Role of Nitroglycerin and Other Nitrogen Oxides in Cardiovascular Therapeutics.
The Role of Nitroglycerin and Other Nitrogen Oxides in Cardiovascular Therapeutics.
复制标题
DOI:
10.1016/j.jacc.2017.09.1064
复制
发表时间:
2017-11-07
影响因子:
24
通讯作者:
Loscalzo J
中科院分区:
文献类型:
--
作者:
Divakaran S;Loscalzo J
The use of nitroglycerin in the treatment of angina pectoris began not long after its original synthesis in 1847. Since then, the discovery of nitric oxide as a biological effector and better understanding of its roles in vasodilation, cell permeability, platelet function, inflammation, and other vascular processes have advanced our knowledge of the hemodynamic (mostly mediated through vasodilation of capacitance and conductance arteries) and non-hemodynamic effects of organic nitrate therapy, via both nitric oxide-dependent and independent mechanisms. Nitrates are rapidly absorbed from mucous membranes, the gastrointestinal tract, and the skin, and, thus, nitroglycerin is available in several preparations for delivery via several routes: oral tablets, sublingual tablets, buccal tablets, sublingual spray, transdermal ointment, and transdermal patch; it is also available in intravenous formulations. The organic nitrates are commonly used in the treatment of cardiovascular disease, but clinical data limit their use mostly to the treatment of angina. They are also used in the treatment of subsets of patients with heart failure and pulmonary hypertension. One major problem with the use of nitrates is the development of tolerance. Although several agents have been studied for use in the prevention of nitrate tolerance, none are currently recommended owing to a paucity of supportive clinical data. Only one method of preventing nitrate tolerance remains widely accepted: the use of a dosing strategy that provides an interval of no or low nitrate exposure during each 24-hour period. Nitric oxide’s important role in several cardiovascular disease mechanisms continues to drive research toward finding novel ways to affect both endogenous and exogenous sources of this key molecular mediator.
登录
查看更多内容
DOI:
10.1073/pnas.74.8.3203
发表时间:
1977-01-01
影响因子:
11.1
作者:
ARNOLD, WP;MITTAL, CK;MURAD, F
通讯作者:
MURAD, F
影响因子:
--
作者:
Chirinos, Julio A;Zamani, Payman
通讯作者:
Zamani, Payman
影响因子:
3.9
作者:
Chen, Yili;Chen, Cong;Dong, Yugang
通讯作者:
Dong, Yugang
DOI:
10.1007/164_2016_100
发表时间:
2017-01-01
期刊:
HEART FAILURE
影响因子:
--
作者:
Breitenstein, Stefanie;Roessig, Lothar;Lewis, Kelly S.
通讯作者:
Lewis, Kelly S.
影响因子:
2.8
作者:
CHRYSANT, SG;GLASSER, SP;CASARETO, R
通讯作者:
CASARETO, R